Research programme: orexin 1 receptor antagonist - AstraZeneca/Eolas

Drug Profile

Research programme: orexin 1 receptor antagonist - AstraZeneca/Eolas

Latest Information Update: 03 Jul 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eolas Therapeutics
  • Developer AstraZeneca
  • Class Drug withdrawal therapies
  • Mechanism of Action Orexin receptor type 1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Drug abuse; Neurological disorders; Smoking withdrawal

Most Recent Events

  • 30 Jun 2015 Eolas orexin-1 receptor antagonist licensed to AstraZeneca worldwide
  • 30 Jun 2015 Eolas Therapeutics receives Blueprint Neurotherapeutics (BPN) grant from National Institutes of Health (NIH) for development of orexin-1 receptor antagonist
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top